Citations

Clear

4610 citation(s) found for "Lu, Brian".

Circulating cell‐free DNA methylation biomarkers for hepatocellular carcinoma risk prediction in HIV ‐positive Nigerian population
Zheng, Yinan , Han, Jingzhe , Qu, Yishu , Wang, Jun , Okeke, Edith, Davwar, Pantong , Duguru, Mary, Nyam, David, Oyeleke, Ganiyat K. , Sulaimon, Akanmu A., Hawkins, Claudia , Badmos, Kabir, Gursel, Demirkan, Silas, Olugbenga A. , Kocherginsky, Masha , Sun, Zequn , Achenbach, Chad J. , Yang, Hushan , Sagay, Atiene S. , Roberts, Lewis R., Hou, Lifang , Roberts, Lewis R. , Yang, Hushan , Roberts, Lewis R , Zheng, Yinan , Hou, Lifang , Wang, Jun , Joyce, Brian , Odeghe, Emuobor , Lesi, Olufunmilayo , Imade, Godwin , Abdulkareem, Fatimah Biade , Wei, Jian‐Jun , Kim, Kwang‐Youn A. , Zhang, Xuehong , Ogunsola, Folasade Tolulope , Murphy, Robert L. , Roberts, Lewis R.

Mayo Clinic

International Journal of Cancer | October 23, 2025 | Volume: 158 | Issue: 5 | Pages: 1281-1291

10.1002/ijc.70204 | PMID 41129333 Get It

Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally, with particularly high burdens among people living with HIV (PLWH) in low‐resource settings like Nigeria. Effective early detection remains a major challenge due to limited access to imaging‐based surveillance and the low sensitivity of current biomarkers such as alpha‐fetoprotein (AFP). We conducted an epigenome‐wide association study (EWAS) of circulating cell‐free DNA (ccfDNA) methylation in a Nigerian cohort of HIV‐positive individuals ( n = 245), spanning HCC, cirrhosis (FibroScan ≥12.3 kPa), fibrosis (FibroScan ≥7.6 and <12.3 kPa), and HCC‐free without fibrosis (FibroScan <7.6 kPa) groups. Using random forest modeling, we developed and evaluated a ccfDNA methylation classifier (ccfDNAmRF) for HCC risk prediction. We identified 73 CpG sites significantly associated with HCC (false discovery rate <0.01). The ccfDNAmRF model demonstrated strong discriminatory power, achieving 100% sensitivity and 80%–91% specificity for distinguishing HCC from cirrhosis, fibrosis, and HCC‐free groups (area under the curve [AUC]: 92%–97%). Combining ccfDNA methylation risk scores with AFP further improved classification accuracy (AUC up to 98.5%). Notably, ccfDNA methylation patterns displayed clear dose–response relationships across the disease spectrum, supporting their utility for early‐stage detection and risk stratification. Our findings highlight the promise of ccfDNA methylation biomarkers as a non‐invasive, blood‐based screening tool for improving early identification of HCC cases among PLWH.
Distinct human small intestinal microbiome communities underlie visceral hypersensitivity in a humanized mouse model
Comba, Işın Y. , Sekhon, Prabhjot Kaur , Edwards, Brian S. , Willits, Adam , Shields‐Cutler, Robin , Bellampalli, Shreya S. , Mercado‐Perez, Arnaldo , Tienter, Dennis R., Till, Lisa , Farrugia, Gianrico, Kashyap, Purna , Louwies, Tijs, Mars, Ruben At, Bellampalli, Shreya, Mercado-Perez, Arnaldo, Smith-Edwards, Kristen M , Comba, Isin Y , Louwies, Tijs , Mars, Ruben A. , Xiao, Yang , Linden, David R. , Farrugia, Gianrico , Beyder, Arthur

Mayo Clinic

Journal of Clinical Investigation | October 23, 2025 | Volume: 135 | Issue: 24 | Pages: No page available

10.1172/jci190638 | PMID 41129263 Get It

Consequences of Delaying Surgical Intervention in Patients With Native Joint Septic Arthritis
Matsuo, Takahiro , Lahr, Brian D. , Saleh, Omar Abu , McHugh, Jack , Zein, Said El , Yuan, Brandon J. , Tande, Aaron J. , Abu Saleh, Omar M, Damronglerd, Pansachee, McHugh, Jack , El Zein, Said , Yuan, Brandon , Tande, Aaron , Matsuo, Takahiro , Khodadadi, Ryan B. , Damronglerd, Pansachee , Suh, Gina A.

Mayo Clinic

Open Forum Infectious Diseases | October 23, 2025 | Volume: 12 | Issue: 11 | Pages: No page available

10.1093/ofid/ofaf662 | PMID 41234298 Get It

Abstract Background Although recent guidance recommends early surgical debridement for native joint septic arthritis (NJSA), supporting data, particularly on long-term outcomes, remains scarce. Methods We conducted a retrospective multicenter cohort study of adults (≥18 years) with NJSA who underwent surgery across Mayo Clinic campuses between 2012 and 2021. Clinical outcomes at 1 year were assessed using a 9-level Desirability of Outcome Ranking (DOOR) scale, incorporating survival, treatment failure (relapse, reinfection, readmission, or significant surgical events), and joint recovery. Time to surgery from hospital admission was analyzed both as a continuous variable and as categories: &lt; 1, 1–2, or ≥3 days. Results Among 268 patients, 30% underwent surgery &lt;1 day from admission, 47% in 1–2 days, and 24% in ≥3 days. At 1 year, 57% achieved full recovery without unfavorable events (DOOR score 1), while treatment failure occurred in 34%. In unadjusted analyses, longer surgical delay was significantly associated with higher (worse) DOOR scores (per IQR increase [from 0 to 2 days], OR: 1.5; 95% CI: 1.0–2.1; P = .026), increased 1-year mortality (HR: 1.7; 95% CI: 1.1–2.6; P = .019) and treatment failure (HR: 1.5; 95% CI: 1.1–2.0; P = .007). Even after adjusting for age and Charlson comorbidity index, the association between surgical delay and treatment failure remained significant (HR: 1.5; 95% CI, 1.1–2.0; P = .016). Conclusions The finding that delayed surgical intervention is associated with an increased risk of treatment failure reinforces current expert recommendations for timely surgical management in NJSA.
Structural changes from wild-type define tumor-rejecting neoantigens
Adams, Anngela C. , Macy, Anne M. , Borden, Elizabeth S. , Herrmann, Lauren M , Brambley, Chad A. , Hughes, Alysia , Roe, Denise J. , Mangold, Aaron R. , Buetow, Kenneth H. , Baker, Brian M. , Hastings, Karen Taraszka , Nikolich, Janko Z , Hastings, K Taraszka , Mangold, A R , Sonar, Sandip Ashok , Ma, Tao , Li, Xing , Nikolich‐Žugich, Janko , Wilson, Melissa Ann

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 23, 2025 | Volume: 13 | Issue: 10 | Pages: e013148

10.1136/jitc-2025-013148 | PMID 41125532 Get It

Background Challenges in predicting which neoantigens mediate tumor rejection limit the efficacy of neoantigen vaccines to treat cancers, especially for cancers with a high mutational burden like cutaneous squamous cell carcinoma (cSCC). Only a small portion of neoantigens prioritized by current methods elicit effective T cell responses, demonstrating the critical need for improved criteria for the prediction of tumor-rejecting neoantigens. Methods Publicly available human cSCC datasets were used to assess the frequency of shared mutations between patients. A transplantable ultraviolet light-induced mouse model of cSCC was generated. The mutational signature and driver mutations in the mouse model were compared with human tumors. Neoantigens were prioritized in the mouse model, and tumor-rejecting neoantigens were identified through (enzyme-linked immunosorbent spot (ELISpot) and in vivo prophylactic vaccination. Binding of the neoantigens and corresponding wild-type peptides to major histocompatibility complex (MHC) class I was determined. Structural modeling of peptide:MHC complexes was performed to assess for changes in structural characteristics of the neoantigens relative to the wild-type peptides. Results A minority of human cSCC tumors shared neoantigens. The mouse cSCC model recapitulated the mutational signature and driver mutations found in human disease and was constrained by CD8 T cells. Two MHC class I neoantigens were identified in the mouse model that constrained cSCC growth. One tumor-rejecting neoantigen exhibited improved MHC binding, and the other had increased solvent accessibility of the mutated residue, compared with wild-type. Across known neoantigens that do not impact MHC binding, increased exposure of the mutated residue distinguished tumor-rejecting from non-immunogenic neoantigens. Conclusions Given the paucity of shared mutations, this work supports the need for personalized neoantigen vaccines in cSCC. To facilitate further discovery, we provide a clinically relevant mouse cSCC model with two defined neoantigens that mediate tumor rejection. Structural changes in the exposure of features that promote T cell receptor recognition defined tumor-rejecting neoantigens. Incorporation of structural modeling to predict changes in T cell receptor accessibility is anticipated to improve the selection of neoantigens for inclusion in personalized cancer vaccines.
Emergency department-initiated palliative care screening among older adults: a systematic review and meta-analysis protocol
Lin, Dimitri E , Mowbray, Fabrice , Isaacs, E. D., Markwalter, Daniel , Hay, Alison , Manfredi, Rita A. , Westlake, Erica , Bowman, Jason , Rebollo-Lee, Naomi, Gacioch, Brian, Brooten, Justin K. , Pajka, Sarah E. , Selman, Katie, Bain, Paul , Liu, Shan W. , Ouchi, Kei , Markwalter, Daniel , Ginsburg, Alexander D, Bain, Paul , Mowbray, Fabrice , Lin, Dimitri E , Gunaga, Satheesh , Isaacs, Eric D, George, Naomi R. , Akhter, Murtaza , Ginsburg, Alexander , Selman, Katherine , Davis, Joshua J.

Mayo Clinic

BMJ Open | October 22, 2025 | Volume: 15 | Issue: 10 | Pages: e095894

10.1136/bmjopen-2024-095894 | PMID 41125269 Get It

Introduction The rapidly growing population of older adults (individuals aged 65 years and older) presents a new set of challenges for healthcare providers in the emergency department (ED), given the prevalence of severe and life-threatening conditions among this group, such as chronic cancer, Alzheimer’s disease/dementia and congestive heart failure. ED encounters often represent a critical point in an older patient’s trajectory of care and can thus be an important opportunity for various interventions such as palliative care consultation. Therefore, identifying those who will benefit most from palliative care is of high importance, especially in determining the course of future treatment. Thus, we aim to conduct a systematic review assessing the efficacy of palliative care screening in the ED by assessing inpatient length of stay as the primary outcome and quality of life, percentage of hospitalisation and cost of care as secondary outcomes. Methods This study will use Ovid MEDLINE, Embase, EBSCO CINAHL, Web of Science and Cochrane as databases. The study population comprises adults aged 60 years and older, with no focus on any specific clinical specialty or disease. Patients who have not received palliative care screening will serve as the comparator. Only studies with an applicable comparator will be considered. Studies published from 1 January 2000 to 1 July 2025 will be included. All articles will be reviewed independently and in duplicate, and every author will participate in the review, data abstraction and conflict resolution process. Ethics and dissemination Ethical approval is not required as it is a protocol for a systematic review. Findings will be disseminated through peer-reviewed publications and conference presentations. PROSPERO registration number CRD42024562389.
Testicular Cancer–Associated Paraneoplastic Neurologic Syndromes
Harahsheh, Ehab , Hammami, M Bakri , Costello, Brian A. , Leibovich, Bradley C. , Cheville, John C. , Ζεκερίδου, Αναστασία , McKeon, Andrew, Dubey, Divyanshu , Leibovich, Bradley, Bakri, Hammami M , Dubey, Divyanshu , Gupta, Pranjal , McKeon, Andrew, Pittock, Sean J.

Mayo Clinic

JAMA Network Open | October 21, 2025 | Volume: 8 | Issue: 10 | Pages: e2538584

10.1001/jamanetworkopen.2025.38584 | PMID 41118166 Get It

This cohort study examines the oncological, neurological, and serological profiles of adult male patients with testicular germ cell tumors and paraneoplastic neurologic syndromes.
The Association of Social Determinants of Health Screening With Developmental and Social-Emotional Outcomes in Children Enrolled in Head Start
Farkouh, Elizabeth K. , Toussaint, Loren , Lynch, Brian , Toussaint, Loren L , Lynch, Brian A , Farkouh, E K

Mayo Clinic

Journal of Primary Care & Community Health | October 19, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251384525 | PMID 41109746 Get It

Introduction/Objectives: Social determinants of health (SDOH) have the potential to differentially impact child developmental outcomes. This study examined whether scores on the Environmental Screening Questionnaire (ESQ), a newly developed SDOH screening tool, were associated with scores on the Brigance and Ages & Stages Questionnaires-Social-Emotional (ASQ:SE-2) child development assessments. Methods: Brigance, ASQ:SE-2, and ESQ scores from children enrolled in a Head Start Program in Northeast Iowa were collected during the 2021 to 2022 and 2022 to 2023 school years. Associations between scores in each ESQ domain and Brigance and ASQ:SE-2 scores were assessed. Results: Education-Employment and Community concerns on the ESQ were associated with reduced Brigance scores ( r = −.21, P < .001; r = −.17, P = .001). Concerns related to Housing, Child and Family Health, and Community were associated with more concerning ASQ:SE-2 scores ( r = .14, P = .005; r = .18, P < .001; r = 0.27, P < .001). In multivariable models controlling for sex and ethnicity, Education-Employment concerns were significant predictors of lower Brigance scores, while Child and Family Health and Community concerns were significant predictors of ASQ:SE-2 scores. Conclusions: ESQ scores in certain SDOH domains correlate significantly with child developmental outcomes. The ESQ domains of Child and Family Health and Community appear to be particularly important for appropriate child socio-emotional development. Interventions should focus on addressing critical SDOH domains to promote child resilience and counteract the non-medical factors that can interfere with child developmental outcomes.
Augmented Reality and 3D Printing as an Aid to Surgical Planning in Modern Microtia Reconstruction
Gomez, Diego A. , Hashemi, Kiana, Sharma, Ishpriya, Demeris, Alexander, Patel, Pushpak , Kellogg, Brian C. , Sharma, Ishpriya , Gomez, Diego A , Sharma, Ishpriya, Aycart, Mario A. , Dusseldorp, Joseph R. , Barone, Angelo A. Leto

Mayo Clinic

Journal of Craniofacial Surgery | October 17, 2025 | Volume: 37 | Issue: 3/4 | Pages: 896-900

10.1097/scs.0000000000012082 | PMID 41105048 Get It

Since Tanzer’s seminal work introducing costal cartilage for ear reconstruction, subsequent advances by Brent, Nagata, and Firmin have refined surgical techniques and aesthetic outcomes. However, fundamental aspects of the procedure—such as planning incisions, achieving accurate ear positioning, and guiding chest wall incisions for rib harvest—have seen limited innovation. The current standard practice of using projection paper or transparent templates to replicate the contralateral ear position remains imprecise. Similarly, autologous cartilage harvest can be particularly challenging in patients with higher BMI, due to difficulty in accurate rib palpation and visualization. Misplaced chest wall incisions can result in suboptimal rib harvest, longer operative times, and increased morbidity. In this study, we introduce patient-specific, three-dimensional (3D) printed masks, termed hEARo masks, as a novel and user-friendly tool for ear framework positioning. Furthermore, we present the integration of augmented reality (AR) technology to enhance preoperative planning and intraoperative guidance during microtia repair, enabling more precise incision placement for rib harvest. The combined use of 3D printing and AR facilitates complex ear reconstruction, offering increased surgical precision, reduced operative time, and potentially improved patient outcomes. These innovations represent a significant advancement in the personalization and accuracy of auricular reconstruction.
Short‐Term Outcomes Following Transurethral Dorsal Buccal Graft Urethroplasty for Female Urethral Strictures
Jefferson, Francis A. , Lee, Yeonsoo Sara , Rafetto, Anessa , Balzano, Felicia, Cohen, Tal , Linder, Brian J. , Warner, J, Rafetto, Anessa N , Sara Lee, Yeonsoo , Linder, Brian J

Mayo Clinic

Neurourology and Urodynamics | October 16, 2025 | Volume: 45 | Issue: 1 | Pages: 155-161

10.1002/nau.70161 | PMID 41097847 Get It

ABSTRACT Introduction and Objectives Female urethral strictures remain a challenging clinical entity with limited data on optimal reconstructive techniques. This study presents 12‐month clinical and patient‐reported outcomes following a novel transurethral approach to dorsal inlay buccal graft urethroplasty. Methods We evaluate the outcomes of consecutive female patients with urethral strictures treated via dorsal inlay buccal graft urethroplasty from October 2021 to November 2024. Preoperative evaluation included cystoscopy, uroflowmetry, and/or voiding cystourethrogram. Follow‐up at 4 and 12 months included cystoscopy, uroflowmetry, and patient‐reported outcomes measured via the Global Response Assessment. Success was defined as absence of recurrence on cystourethroscopy. Results Twenty‐one patients were included in the study, with 95% having undergone prior treatments (90% dilation/DVIU and 9% urethroplasty). Stricture locations varied across the distal (33%), mid (19%), proximal (19%), and multifocal/pan urethral (19%). The median operative duration was 60 min (IQR: 56–86) and all were discharged on the day of surgery. Nineteen patients (90%) underwent a dorsal inlay procedure, while two (10%) required combined dorsal and ventral inlay due to obliterative stricture. No complications were observed. The median follow‐up was 13.2 (IQR: 5.1–23.5) months, during which time 1 patient underwent retreatment for recurrent stricture. Clinical success was 95% at 4 months and 92% at 12 months. Median peak urinary flow rate preoperatively versus 4‐month postoperatively was 7.0 cc/s versus 13.0 cc/s ( p = 0.20) and at 12‐month postoperatively was 13.3 cc/s ( p = 0.50). 90% of patients reported improvement on the Global Response Assessment. There were no cases of de novo stress urinary incontinence. Conclusions This novel transurethral dorsal inlay buccal graft urethroplasty offers a safe and efficient treatment for female urethral strictures with durable clinical and patient‐reported outcomes at 12 months. The technique's minimal urethral mobilization translates into shorter operative times and a low risk of stress incontinence, making it a promising alternative to traditional approaches.
PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study
Reed, Damon R. , Janeway, Katherine A. , Hall, David , Crompton, Brian D. , Wang, Wei‐Lien , Zylber, Rebecca, Contreras, Alejandro , Carrero, Giselle, Voss, Stephan D. , Militano, Olga, Pickett, Cheryl A., Fox, Elizabeth , Weigel, Brenda J. , Teachey, David T , Crompton, Brian D , Lazar, Alexander J , Wang, Wei-Lien , Contreras, Alejandro , Voss, Stephan D , Reid, Joel M , Safgren, Stephanie L , Gorlick, Richard , Fox, Elizabeth , Weigel, Brenda J , Reed, Damon R , Minard, Charles G. , Lazar, Alexander J. , Reid, Joel M. , Safgren, Stephanie L. , Görlick, Richard

Mayo Clinic

JCO Oncology Advances | October 14, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-25-00094 | PMID 42131734 Get It

PURPOSE Human epidermal growth factor receptor 2 (HER2), a transmembrane receptor with kinase activity involved in cell signaling through the RAS pathway, is expressed in osteosarcoma (OST). Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate with a HER2-targeting monoclonal antibody, trastuzumab, linked to a topoisomerase I inhibitor. We report results of a phase II study of T-DXd in adolescents and young adults with HER2-positive relapsed, unresectable OST (ClinicalTrials.gov identifier: NCT04616560 ). METHODS Patients age 12-39 years with relapsed, unresectable OST were eligible for centrally evaluated HER2 expression screening by immunohistochemistry. Patients with >10% of OST cells with cytoplasmic or membranous HER2 expression of any intensity were eligible to receive T-DXd at 5.4 mg/kg intravenously once every 3 weeks for up to 2 years. The study used a 9 + 15 Simon's optimal two-stage design with a primary end point of event-free survival at 24 weeks. RESULTS Fifty patients were screened for HER2, and 41 met the inclusion criteria of 10% of OST cells having membranous or cytoplasmic HER2 expression. Nine eligible patients, two younger than 18 years, were enrolled and received T-DXd. With a single patient having more than 24 weeks of stable disease (SD) of the nine planned in the first stage, this study did not meet criteria to progress to stage II. The estimated SD rate at 24 weeks is 11.1%. The median (range) number of cycles of therapy was 2 (2-12). Grade 3 and 4 possibly related adverse events occurred in three of nine patients and included nausea, vomiting, tumor hemorrhage, cytopenias (n = 3), wound infection, and hypertension. CONCLUSION T-DXd did not demonstrate sufficient activity to expand enrollment to the planned second stage in patients with OST. No new safety signals were observed.